BioMarin Likely Able to Support New Prospects, Wedbush Says

11:21 AM EST, 11/03/2026 (MT Newswires) -- BioMarin Pharmaceuticals' (BMRN) revenue stream will likely able to provide support for new growth opportunities, Wedbush said in a note Tuesday, following the company's Q3 results. The report pointed to weak Voxzogo revenue and lower guidance to a drop in the share price following the results. The note, citing the firm, said the guidance reflects changes in order timing instead of patient demand, expecting Voxzogo to grow in 2027 and potential approvals for hypochondroplasia. "We continue to believe that BMRN's strengthened revenue stream should provide a strong support for multiple new growth opportunities," the report said. Wedbush kept its outperform rating while lowering its price target to $89 from $94. Price: 54.65, Change: -2.79, Percent Change: -4.86